ciprofibrate,
Hyperlipen,
Lipanor,
Modalim,
Oroxadin,
Win 35,833,
Ciprofibrate,
52214-84-3,
Lipanor,
2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoic acid,
Ciprofibratum,
Ciprofibrato,
Modalim,
2-[4-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid,
Win-35833,
Ciprofibratum [INN-Latin],
Ciprofibrato [INN-Spanish],
WIN 35833,
CCRIS 173,
C13H14Cl2O3,
EINECS 257-744-6,
Propanoic acid, 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methyl-,
BRN 1984981,
2-(4-(2,2-Dichlorocyclopropyl)phenoxy)2-methylpropanoic acid,
2-(p-(2,2-Dichlorocyclopropyl)phenoxy)-2-methylpropionic acid,
CHEBI:50867,
KPSRODZRAIWAKH-UHFFFAOYSA-N,
MFCD00467135,
NCGC00164447-01,
AK-77509,
2-[p-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid,
2-{[4-(2,2-dichlorocyclopropyl)phenyl]oxy}-2-methylpropanoic acid,
DSSTox_CID_331,
Propanoic acid, 2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methyl-,
DSSTox_RID_75519,
DSSTox_GSID_20331,
Hiperlipen,
Ciprol,
2-{4-[2,2-dichlorocyclopropyl]phenoxy}-2-methylpropanoic acid,
Propionic acid, 2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methyl-,
SMR000857190,
Ciprofibrate [USAN:BAN:INN],
Win 35,833,
SR-01000075734,
Ciprofibrate (USAN/INN),
2-[p-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropionic acid,
Ciprofibrate?,
Ciprofibrate [USAN:INN:BAN],
CAS-52214-84-3,
AC1L1EET,
Prestwick0_001076,
Prestwick1_001076,
Prestwick2_001076,
Prestwick3_001076,
C 0330,
Lopac0_000168,
SCHEMBL26870,
BSPBio_001092,
MLS002154143,
MLS006011758,
Win35833,
SPBio_002996,
2-[4-(2,2-dichlorocyclopropyl)phenoxy]isobutyric acid,
BPBio1_001202,
CHEMBL557555,
GTPL3438,
DTXSID8020331,
CTK7I5107,
KS-00000FXC,
AOB6803,
BCPP000277,
HMS1571G14,
HMS2098G14,
HMS2235J14,
HMS3260B17,
HMS3369B22,
HMS3656P09,
HMS3715G14,
Pharmakon1600-01502008,
BCP03728,
EBD38709,
HY-B0664,
Tox21_112121,
Tox21_201359,
Tox21_302840,
Tox21_500168,
AN-880,
ANW-46062,
BBL010821,
BDBM50371235,
BG0457,
NSC759617,
s2665,
STK624758,
AKOS005557843,
Tox21_112121_1,
AC-1018,
API0002026,
BCP9000533,
CCG-204263,
CS-2898,
KS-1201,
LP00168,
LS-7279,
MCULE-8060052925,
NSC-759617,
RP29995,
NCGC00015202-02,
NCGC00015202-03,
NCGC00015202-04,
NCGC00015202-05,
NCGC00015202-06,
NCGC00015202-08,
NCGC00093652-01,
NCGC00093652-02,
NCGC00256361-01,
NCGC00258911-01,
NCGC00260853-01,
4CA-0385,
BC207557,
CC-25814,
BCP0726000148,
AB0010540,
AB2000704,
AX8121411,
RT-004891,
AB00514032,
EU-0100168,
FT-0602946,
ST24027521,
SW197242-4,
D03521,
AB00514032_06,
214C843,
A828985,
C-18160,
I14-0695,
J-520054,
SR-01000075734-1,
SR-01000075734-4,
SR-01000075734-7,
BRD-A49358627-001-03-9,
BRD-A49358627-001-10-4,
2-[4-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropionic Acid,
Ciprofibrate, European Pharmacopoeia (EP) Reference Standard,
2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methyl-propanoic acid,
2-[4-[2,2-bis(chloranyl)cyclopropyl]phenoxy]-2-methyl-propanoic acid,
Ciprofibrate for system suitability, European Pharmacopoeia (EP) Reference Standard,
Oroxadin,
Hyperlipen,
null,
Ciprofibrate D6,
UNII-F8252JGO9S,
D0EJ6O,
F8252JGO9S,
CID2763,
C13-H14-Cl2-O3,
Sanofi Winthrop brand of ciprofibrate,
ACN-001467,
CS-O-01196,
Sanofi Synthelabo brand of ciprofibrate,
C2667,
C019304,